We seek to establish a framework that the global health community can leverage to assess the health and economic impact of the past 20 years of investment in R&D for neglected diseases and emerging infectious diseases. The resulting insights will aim to inform investment decisions, tradeoffs or required shifts in the product development ecosystem.